CrossrefInfokarte
Efficacy and Safety of Subcutaneous Pertuzumab–Trastuzumab (Phesgo) in Neoadjuvant Treatment of HER2-positive Breast Cancer: Real-world Data from Japan
Anticancer Research · 2026-01 · 46 (1) · 293-300
DOI: 10.21873/anticanres.17943 ↗Abstract
Kein Abstract verfügbar.
EUVIMED